NCT05778643 is a NA clinical trial of TaKeTiNa music therapy in Major Depressive Disorder, sponsored by University of Erlangen-Nürnberg Medical School.

Who is sponsoring NCT05778643?

NCT05778643 is sponsored by University of Erlangen-Nürnberg Medical School.

What drugs are being tested in NCT05778643?

Interventions in NCT05778643: TaKeTiNa music therapy.

What condition does NCT05778643 study?

NCT05778643 studies Major Depressive Disorder.

Is NCT05778643 still recruiting?

NCT05778643 is currently status unknown. Last updated 22 March 2023.

Last reviewed 2023-03-22 · How we verify

NCT05778643

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TaKeTiNa in the Treatment of Depression: a Pilot Study.

Status unknown NA Last updated 22 March 2023

What this trial tests

NA trial testing TaKeTiNa music therapy in Major Depressive Disorder in 120 participants. Status unknown.

Timeline

1 March 2023

Primary endpoint
14 February 2024

15 February 2024

Quick facts

Lead sponsor	University of Erlangen-Nürnberg Medical School
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	1 March 2023
Primary completion	14 February 2024
Estimated completion	15 February 2024
Sites	1 location across Germany

Drugs / interventions tested

TaKeTiNa music therapy

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

University of Erlangen-Nürnberg Medical School

Who can join

Adults 18 to 75, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical study's to analyse the impact of TaKeTiNa music therapy in depressed patients. The main question\[s\] it aims to answer are: . Can TaKeTiNa result in a significant pre-to-post intervention decline of depression severity 2. Can TaKeTiNa result in a significantly lower post-intervention depression severity in the T1/T2 group than in the W1/W2 group. Participants will * be randomly assigned to the two groups, intervention vs. waitlist * receive either an eight week TaKeTiNa music therapy or waitlist * be analysed using questionaires, blood taking, cortisol saliva analysis, measured heart rate variability Researchers will compare a waitlist to see if TakeTiNa is superior to waitlist

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

TaKeTiNa Music Therapy for Outpatient Treatment of Depression: Study Protocol for a Randomized Clinical Trial.
Behzad A, Feldmann-Schulz C, Lenz B, Clarkson L, et al · · 2024 · cited 1× · PMID 38731019 · DOI 10.3390/jcm13092494
TriCAM (NCT02976558) - a randomized controlled pilot study of complementary medicine in allogeneic stem cell transplantation to improve quality of life.
Behzad A, Krause SW, Mackensen A, Müller F, et al · · 2025 · PMID 40922037 · DOI 10.1186/s12906-025-05058-8

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other University of Erlangen-Nürnberg Medical School trials

Trials by the same sponsor.

NCT06969820 — Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT · not yet recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07352540 — Single vs Triple Hyaluronic Acid in Knee Osteoarthritis · Phase 2, PHASE3 · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT07121985 — Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré S · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05778643 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Erlangen-Nürnberg Medical School
Last refreshed: 22 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05778643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing